bile metabolism, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, bile metabolism

Abrahamsson A, Krapivner S, Gustafsson U, Muhrbeck O, Eggertsen G, Johansson I, Persson I, Angelin B, Ingelman-Sundberg M, Bjorkhem I, Einarsson C, Hooft FM 2005 Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. Atherosclerosis 182: 37-45.
Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M 2005 Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res. 46: 46-57. *
Alnounou M, Munoz SJ 2006 Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100. *
Alvarez L, Jara P, Sanchez-Sabate E, Hierro L, Larrauri J, Diaz MC, Camarena C, De La Vega A, Frauca E, Lopez-Collazo E, Lapunzina P 2004 Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13: 2451-2460. *
Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D, Darlington G 2007 Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell 6: 453-470.
Angelin B 2005 Telling the liver (not) to make bile acids: a new voice from the gut? Cell. Metab. 2: 209-210. *
Angelin B, Eriksson M, Parini P, Rudling M 2004 Bile acids and lipoproteins. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 31. June 18-19. *
Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44.
Angulo P, Lindor KD 1999 Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570. *
Arrese M, Trauner M 2003 Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9: 558-564. *
Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254.
Azad Khan AK, Truelove SC, Aronson JK 1982 The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br. J. Clin. Pharmacol. 13: 523-528.
Azer SA 2005 A multimedia CD-ROM tool to improve student understanding of bile salts and bilirubin metabolism: evaluation of its use in a medical hybrid PBL course. Adv. Physiol. Educ. 29: 40-50. *
Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M 2008 Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 28: 948-958. *
Balistreri WF 1997 Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589.
Balistreri WF 2003 Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R 2005 Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 2560-2568. *
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B 2003 Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278: 32852-32860. *
Barnes DS 2002 Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
Barth A, Braun J, Muller D 2006 Influence of verapamil and cyclosporin A on bile acid metabolism and transport in rat liver slices. Exp. Toxicol. Pathol. 58: 31-37. *
Barth A, Braun J, Muller D 2006 Bile acid transport and metabolism in rat liver slices. Exp. Toxicol. Pathol. 57: 313-319.
Batta AK, Salen G, Abroon J 1997 Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am. J. Gastroenterol. 92: 1035-1037.
Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S 1989 Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 10: 414-419.
Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, Abroon J, O'Brien CB, Senior JR 1993 Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 88: 691-700.
Bayliss M, Somers G 2004 Isolation and culture of human hepatocytes. Methods Mol. Med. 107: 249-268.
Beath SV 2003 Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346.
Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR 2002 Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. 293: 145-149. *
Bender S, Sauer H, Hoffmann D 1975 Kinetics of bile acid metabolism in experimental blind loop syndrome. Gut 16: 927-931. *
Berard AM, Dumon MF, Darmon M 2004 Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion. FEBS Lett. 559: 125-128. *
Bergasa NV 2005 The pruritus of cholestasis. J. Hepatol. 43: 1078-1088. *
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *
Berger A, Roberts MA, Hoff B 2006 How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome. Lipids Health Dis. 5: 10. *
Bertok L 2004 Bile acids in physico-chemical host defence. Pathophysiology 11: 139-145.
Bertolami MC 2005 Mechanisms of hepatotoxicity. Arq. Bras. Cardiol. 85 Suppl. 4: 25-27.
Bertolotti M, Gabbi C, Anzivino C, Crestani M, Mitro N, Del Puppo M, Godio C, De Fabiani E, Macchioni D, Carulli L, Rossi A, Ricchi M, Loria P, Carulli N 2007 Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur. J. Clin. Invest. 37: 501-508. *
Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N 2006 Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. Eur. J. Clin. Invest. 36: 170-175.
Beuers U 2003 Mechanisms of action of ursodeoxycholic acid in cholestasis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 49-50. October 15-16. *
Beuers U, Fischer S, Spengler U, Paumgartner G 1991 Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. J. Hepatol. 13: 97-103.
Bhalla S, Ozalp C, Fang S, Xiang L, Kemper JK 2004 Ligand-activated PXR interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha: functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279: 45139-45147. *
Bishop-Bailey D 2004 FXR as a novel therapeutic target for vascular disease. Drug News Perspect. 17: 499-504.
Bishop-Bailey D, Walsh DT, Warner TD 2004 Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. U.S.A. 101: 3668-3673. *
Bisschop PH, Bandsma RH, Stellaard F, Ter Harmsel A, Meijer AJ, Sauerwein HP, Kuipers F, Romijn JA 2004 Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am. J. Clin. Nutr. 79: 570-576. *
Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H 2002 Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37: 62-67.
Bjornsson E, Chapman RW 2003 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275.
Blazovics A 2007 Gallstone disease: free radical reactions and the ambivalent role of bilirubin in the pathomechanism of gallstone formation. Orv. Hetil. 148: 589-596.
Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F 2004 Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia 47: 104-112. *
Boberg KM, Lundin KE, Schrumpf E 1994 Etiology and pathogenesis in primary sclerosing cholangitis. Scand. J. Gastroenterol. Suppl. 204: 47-58.
Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH 2008 Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat. Med. 14: 828-836. *
Bodin K 2004 Role of CYP3A4 as a cholesterol and bile acid metabolizing enzyme. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 25. June 18-19. *
Bodin K, Lindbom U, Diczfalusy U 2005 Novel pathways of bile acid metabolism involving CYP3A4. Biochim. Biophys. Acta 1687: 84-93. *
Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B 2003 Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278: 23529-23537. *
Borst P, de Wolf C, van de Wetering K 2007 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453: 661-673. *
Borst P, Oude Elferink RP 2002 Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71: 537-592. *
Bouscarel B, Ceryak S, Robins SJ, Fromm H 1995 Studies on the mechanism of the ursodeoxycholic acid-induced increase in hepatic low-density lipoprotein binding. Lipids 30: 607-617.
Boyer JL 2007 New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46: 365-371. *
Boyer JL 2005 Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740. *
Bremmelgaard A, Alme B 1980 Analysis of plasma bile acid profiles in patients with liver diseases associated with cholestasis. Scand. J. Gastroenterol. 15: 593-600.
Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, Bruining HA 2004 Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J. Antimicrob. Chemother. 54: 199-205. *
Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M 2007 Genome-wide analysis of PPARalpha activation in murine small intestine. Physiol. Genomics 30: 192-204. *
Burkard I, von Eckardstein A, Rentsch KM 2005 Differentiated quantification of human bile acids in serum by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 826: 147-159. *
Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T 2008 Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3: e2267. *
Buters JT, Zysset T, Reichen J 1993 Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem. Pharmacol. 46: 983-991.
Cai SY, Boyer JL 2006 FXR: a target for cholestatic syndromes? Expert Opin. Ther. Targets 10: 409-421.
Cao WM, Murao K, Imachi H, Yu X, Dobashi H, Yoshida K, Muraoka T, Kotsuna N, Nagao S, Wong NC, Ishida T 2004 Insulin like growth factor-I regulation of hepatic scavenger receptor class BI. Endocrinology 145: 5540-5547. *
Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, Kusters JG 2008 Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am. J. Gastroenterol. 103: 1510-1516. *
Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B 2006 The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281: 11039-11049. *
Carnahan VE, Redinbo MR 2005 Structure and function of the human nuclear xenobiotic receptor PXR. Curr. Drug Metab. 6: 357-367.
Carulli N, Ponz de Leon M, Zironi F, Iori R, Loria P 1980 Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. Gastroenterology 79: 637-641.
Carulli N, Ponz De Leon M, Zironi F, Pinetti A, Smerieri A, Iori R, Loria P 1980 Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J. Lipid Res. 21: 35-43. *
Castro J, Amigo L, Miquel JF, Galman C, Crovari F, Raddatz A, Zanlungo S, Jalil R, Rudling M, Nervi F 2007 Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45: 1261-1266. *
Cha JY, Repa JJ 2007 The liver X receptor and hepatic lipogenesis: the carbohydrate-response element binding protein is a target gene of LXR. J. Biol. Chem. 282: 743-751. *
Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.
Chatterjee B, Echchgadda I, Song CS 2005 Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400: 165-191.
Chen J, Raymond K 2006 Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml).
Cheng JB, Motola DL, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW 2004 Identification and characterization of CYP2R1, a microsomal vitamin D 25-hydroxylase. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 21. June 18-19. *
Cheung C, Akiyama TE, Kudo G, Gonzalez FJ 2003 Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol. 66: 2011-2020. *
Chiang JY 2005 Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr. Opin. Investig. Drugs 6: 994-1001.
Chiang JY 2002 Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463. *
Chow EK, Castrillo A, Shahangian A, Pei L, O'Connell RM, Modlin RL, Tontonoz P, Cheng G 2006 A role for IRF3-dependent RXRalpha repression in hepatotoxicity associated with viral infections. J. Exp. Med. 203: 2589-2602. *
Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B 2003 Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125: 544-555. *
Claudel T, Staels B, Kuipers F 2005 The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25: 2020-2030. *
Claudel T, Sturm E, Kuipers F, Staels B 2004 The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13: 1135-1148.
Clayton PT 1991 Inborn errors of bile acid metabolism. J. Inherit. Metab. Dis. 14: 478-496.
Cohen BI, Hofmann AF, Mosbach EH, Stenger RJ, Rothschild MA, Hagey LR, Yoon YB 1986 Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit. Gastroenterology 91: 189-197.
Cohran VC, Heubi JE 2003 Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415.
Coleman JP, Kirby LC, Setchell KD, Hylemon PB, Pandak M, Heuman DM, Vlahcevic ZR 1998 Metabolic fate and hepatocyte toxicity of reverse amide analogs of conjugated ursodeoxycholate in the rat. J. Steroid Biochem. Mol. Biol. 64: 91-101.
Colombo C, Apostolo MG, Assaisso M, Roman B, Bottani P 1992 Liver disease in cystic fibrosis. Neth. J. Med. 41: 119-122.
Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A 1992 Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 15: 677-684.
Coltorti M, Bortolini M, Di Padova C 1990 A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find. Exp. Clin. Pharmacol. 12: 69-78.
Cornelius CE, Bruss ML 1980 Hepatic bile pigment excretion and erythrocyte turnover in various species. Vet. Clin. Pathol. 9: 15-20.
Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, Favre CO, Rodriguez Garay EA, Mottino AD, Coleman R, Roma MG 2001 Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 34: 329-339. *
Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell KD 1991 Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 13: 1076-1083.
Crotty B 1994 Ulcerative colitis and xenobiotic metabolism. Lancet 343: 35-38.
Cuevas MJ, Almar M, Gonzalez-Gallego J 2002 Effects of epomediol on ethinyloestradiol-induced changes in glutathione homeostasis in the rat. Pharmacol. Toxicol. 90: 121-126. *
Cui J, Heard TS, Yu J, Lo JL, Huang L, Li Y, Schaeffer JM, Wright SD 2002 The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. J. Biol. Chem. 277: 25963-25969. *
Cui NQ, Zhang SK, Cui YF, Li DH, Chen C, Wu XZ 2005 Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones. Hepatobiliary Pancreat Dis. Int. 4: 117-120. *
Cuthbert JA 1995 Wilson's disease: a new gene and an animal model for an old disease. J. Investig. Med. 43: 323-336.
Dastani Z, Engert JC, Genest J, Marcil M 2006 Genetics of high-density lipoproteins. Curr. Opin. Cardiol. 21: 329-335.
Dawson PA, Rao A, Craddock AL, Haywood J 2006 Analysis of the molecular mechanisms responsible for intestinal basolateral bile acid transport. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 43. *
De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M 2003 Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 278: 39124-39132. *
De Fabiani E, Mitro N, Godio C, Gilardi F, Caruso D, Crestani M 2004 Bile acid signaling to the nucleus: finding new connections in the transcriptional regulation of metabolic pathways. Biochimie 86: 771-778.
Deng R 2007 Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc. Drug Rev. 25: 375-390.
Denk GU, Cai SY, Chen WS, Lin A, Soroka CJ, Boyer JL 2006 A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. World J. Gastroenterol. 12: 2536-2548. *
Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16. *
Dietrich CG, Geier A, Wasmuth HE, Matern S, Gartung C, de Waart DR, Elferink RP 2004 Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. Gut 53: 1850-1855. *
Dixit M, Choudhuri G, Keshri LJ, Mittal B 2006 Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease. J. Gastroenterol. Hepatol. 21: 847-849. *
Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, Punreddy S, Hirsch D, Watson N, Gimeno RE, Stahl A 2006 Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130: 1245-1258. *
Doherty MM, Poon K, Tsang C, Pang KS 2006 Transport is not rate-limiting in morphine glucuronidation in the single pass perfused rat liver preparation. J. Pharmacol. Exp. Ther. 317: 890-900. *
Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM 2003 A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11: 1079-1092. *
Duan RD 2006 Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim. Biophys. Acta 1761: 281-291. *
Dubrac S, Lear SR, Ananthanarayanan M, Balasubramaniyan N, Bollineni J, Shefer S, Hyogo H, Cohen DE, Blanche PJ, Krauss RM, Batta AK, Salen G, Suchy FJ, Maeda N, Erickson SK 2005 Role of CYP27A in cholesterol and bile acid metabolism. J. Lipid Res. 46: 76-85. *
Dueland S, Reichen J, Everson GT, Davis RA 1991 Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem. J. 280: 373-377.
Duez H, Veen JV, Duhem C, Pourcet B, Touvier T, Fontaine C, Derudas B, Bauge E, Havinga R, Bloks VW, Wolters H, van der Sluijs FH, Vennstrom B, Kuipers F, Staels B 2008 Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 135: 689-698.e5. *
Duran-Sandoval D, Cariou B, Fruchart JC, Staels B 2005 Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87: 93-98.
Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B 2005 The farnesoid X receptor modulates hepatic carbohydrate metabolism during fasting/refeeding transition. J. Biol. Chem. 280: 29971-29979. *
Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, Kuipers F, Staels B 2004 Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53: 890-898. *
Echchgadda I, Song CS, Oh T, Ahmed M, De La Cruz IJ, Chatterjee B 2007 The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. Mol. Endocrinol. 21: 2099-2111. *
Echchgadda I, Song CS, Roy AK, Chatterjee B 2004 Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 65: 720-729. *
Edwards PA, Kast HR, Anisfeld AM 2002 BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 2-12. *
Eghdamian B, Ghose K 1998 Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc.) 34: 943-956.
Eipel C, Eisold M, Schuett H, Vollmar B 2007 Inhibition of heme oxygenase-1 protects against tissue injury in carbon tetrachloride exposed livers. J. Surg. Res. 139: 113-120. *
Elias E, Mills CO 2007 Coordinated defence and the liver. Clin. Med. 7: 180-184.
Eliseo T, Ragona L, Catalano M, Assfalg M, Paci M, Zetta L, Molinari H, Cicero DO 2007 Structural and dynamic determinants of ligand binding in the ternary complex of chicken liver bile acid binding protein with two bile salts revealed by NMR. Biochemistry 46: 12557-12567. *
Ellis EC 2006 Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World J. Gastroenterol. 12: 4640-4645. *
Eloranta JJ, Kullak-Ublick GA 2005 Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433: 397-412. *
Erickson JM, Mawson AR 2000 Possible role of endogenous retinoid (vitamin A) toxicity in the pathophysiology of primary biliary cirrhosis. J. Theor. Biol. 206: 47-54. *
Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G 2003 Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009. *
Eusufzai S, Ericsson S, Cederlund T, Einarsson K, Angelin B 1991 Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 32: 1044-1048. *
Everson GT, Fennessey P, Kern F Jr 1988 Contraceptive steroids alter the steady-state kinetics of bile acids. J. Lipid Res. 29: 68-76. *
Falany CN, Xie X, Wheeler JB, Wang J, Smith M, He D, Barnes S 2002 Molecular cloning and expression of rat liver bile acid CoA ligase. J. Lipid Res. 43: 2062-2071. *
Fayard E, Schoonjans K, Auwerx J 2001 Xol INXS: role of the liver X and the farnesol X receptors. Curr. Opin. Lipidol. 12: 113-120.
Feuer G, Di Fonzo CJ 1992 Intrahepatic cholestasis: a review of biochemical-pathological mechanisms. Drug Metabol. Drug Interact. 10: 1-161.
Fickert P, Moustafa T, Fuchsbichler A, Claudel T, Halilbasic E, Kratky D, Zatloukal K, Denk H, Trauner M 2008 Differential effects of ursodeoxycholic acid (UDCA) and sidechain-shortened norUDCA in the treatment of fatty liver and atherosclerosis. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 54. *
Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M 2006 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481. *
Figge A, Matern S, Lammert F 2002 Molecular genetics of cholesterol cholelithiasis: identification of human and murine gallstone genes. Z. Gastroenterol. 40: 425-432.
Fitzgerald ML, Moore KJ, Freeman MW 2002 Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 80: 271-281. *
Fletcher N, Wahlstrom D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Hakansson H 2005 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 207: 1-24. *
Fon Tacer K, Kuzman D, Seliskar M, Pompon D, Rozman D 2007 TNF-alpha interferes with lipid homeostasis and activates acute and pro-atherogenic processes. Physiol. Genomics 31: 216-227. *
Francis GA, Fayard E, Picard F, Auwerx J 2003 Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311. *
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.
Frank C, Makkonen H, Dunlop TW, Matilainen M, Vaisanen S, Carlberg C 2005 Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol. 346: 505-519. *
Frederiksen SL, Chen W 2004 D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD004182. *
Fuchs M 2003 Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G551-G557. *
Fujino T, Une M, Imanaka T, Inoue K, Nishimaki-Mogami T 2004 Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. J. Lipid Res. 45: 132-138. *
Fujiwara K 1989 Clinical examination of serum bile acids for the diagnosis of hepatobiliary diseases. Rinsho Byori 37: 1114-1121.
Fukuchi J, Song C, Dai Q, Hiipakka RA, Liao S 2005 5beta-Cholane activators of the farnesol X receptor. J. Steroid Biochem. Mol. Biol. 94: 311-318.
Fukumoto Y, Okita K, Kodama T, Noda K, Harada T, Mizuta M, Takemoto T 1980 Studies of alpha-napthylisothiocyanate-induced hepatic disturbance. Hepatogastroenterology 27: 457-464.
Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A 1990 Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 12: 486-491.
Galman C, Angelin B, Rudling M 2005 Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129: 1445-1453. *
Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M 2003 Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267. *
Gbaguidi GF, Agellon LB 2002 The atypical interaction of peroxisome proliferator-activated receptor alpha with liver X receptor alpha antagonizes the stimulatory effect of their respective ligands on the murine cholesterol 7alpha-hydroxylase gene promoter. Biochim. Biophys. Acta 1583: 229-236. *
Geier A, Dietrich CG, Grote T, Beuers U, Prufer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, Bilzer M 2005 Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol. 43: 1021-1030. *
Gems D 2007 Long-lived dwarf mice: are bile acids a longevity signal? Aging Cell 6: 421-423.
Ghose R, Zimmerman TL, Thevananther S, Karpen SJ 2004 Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: a novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept. 2: 4. *
Gimeno RE 2007 Fatty acid transport proteins. Curr. Opin. Lipidol. 18: 271-276.
Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, Hum DW, Fruchart JC, Staels B 2008 Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. Aug 28 [Epub ahead of print]. *
Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA 2004 Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14: 635-645.
Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, Repa JJ 2003 Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 100: 223-228. *
Goodwin B, Kliewer SA 2002 Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G926-G931. *
Grattagliano I, Portincasa P, Palmieri VO, Palasciano G 2005 Contribution of canalicular glutathione efflux to bile formation. From cholestasis associated alterations to pharmacological intervention to modify bile flow. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 153-161.
Green RM, Hoda F, Ward KL 2000 Molecular cloning and characterization of the murine bile salt export pump. Gene 241: 117-123. *
Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G 1993 Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch. Dis. Child. 69: 141-143.
Groen AK 2006 The emerging role of bile acids as integrators of intermediary metabolism. J. Hepatol. 45: 337-338. *
Groneberg DA, Grosse-Siestrup C, Fischer A 2002 In vitro models to study hepatotoxicity. Toxicol. Pathol. 30: 394-399. *
Gross JB Jr, Ludwig J, Wiesner RH, McCall JT, LaRusso NF 1985 Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 89: 272-278.
Gruy-Kapral C, Little KH, Fordtran JS, Meziere TL, Hagey LR, Hofmann AF 1999 Conjugated bile acid replacement therapy for short-bowel syndrome. Gastroenterology 116: 15-21. *
Guariento M, Raimondo D, Assfalg M, Zanzoni S, Pesente P, Ragona L, Tramontano A, Molinari H 2008 Identification and functional characterization of the bile acid transport proteins in non-mammalian ileum and mammalian liver. Proteins 70: 462-472.
Gueguen Y, Souidi M, Baudelin C, Dudoignon N, Grison S, Dublineau I, Marquette C, Voisin P, Gourmelon P, Aigueperse J 2006 Short-term hepatic effects of depleted uranium on xenobiotic and bile acid metabolizing cytochrome P450 enzymes in the rat. Arch. Toxicol. 80: 187-195. *
Guengerich FP 2003 Cytochromes P450, drugs, and diseases. Mol. Intervent. 3: 194-204. *
Guitaoui M, Parquet M, Aubert C, Montet AM, Montet JC 2004 Conjugation with taurine prevents side-chain desaturation of ursodeoxycholic and beta-muricholic acids in bile fistula rats. Fundam. Clin. Pharmacol. 18: 457-464. *
Guldutuna S, Leuschner M, Wunderlich N, Nickel A, Bhatti S, Hubner K, Leuschner U 1993 Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function. Eur. J. Clin. Pharmacol. 45: 221-225.
Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O 2002 The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 49: 497-500.
Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ 2003 Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071. *
Gustafsson J, Alvelius G, Bjorkhem I, Nemeth A 2006 Bile acid metabolism in extrahepatic biliary atresia: lithocholic acid in stored dried blood collected at neonatal screening. Ups. J. Med. Sci. 111: 131-136.
Hagenauer B, Maier-Salamon A, Thalhammer T, Zollner P, Senderowicz A, Jager W 2004 Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. Oncol. Rep. 11: 1069-1075.
Halpern MD, Dvorak B 2008 Does abnormal bile acid metabolism contribute to NEC? Semin. Perinatol. 32: 114-121. *
Handschin C, Meyer UA 2003 Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55: 649-673. *
Handschin C, Podvinec M, Amherd R, Looser R, Ourlin JC, Meyer UA 2002 Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J. Biol. Chem. 277: 29561-29567. *
Hanniman EA, Lambert G, McCarthy TC, Sinal CJ 2005 Loss of functional farnesoid X-receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46: 2595-2604. *
Hardison WG, Grundy SM 1983 Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology 84: 617-620.
Haussinger D, Schliess F 2007 Glutamine metabolism and signaling in the liver. Front. Biosci. 12: 371-391.
He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S 2006 Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98: 192-199. *
Hegele RA, Robinson JF 2005 ABC transporters and sterol absorption. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 31-37.
Hempfling W, Dilger K, Beuers U 2003 Ursodeoxycholic acid - adverse effects and drug interactions. Aliment. Pharmacol. Ther. 18: 963-972. *
Henderson CJ, Wolf CR 2003 Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Intervent. 3: 331-343. *
Heubi JE, Setchell KD, Bove KE 2007 Inborn errors of bile acid metabolism. Semin. Liver Dis. 27: 282-294.
Higashiyama H, Kinoshita M, Asano S 2008 Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem. 110: 86-93.
Higuchi H, Gores GJ 2003 Mechanisms of liver injury: an overview. Curr. Mol. Med. 3: 483-490.
Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R 2004 Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J. Biol. Chem. 279: 45685-45692. *
Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB 2006 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806. *
Hobbs HH, Cohen JC 2004 ABCG5 and ABCG8 play major role in defense against sterol accumulation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 55. June 18-19. *
Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE 1985 Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur. J. Clin. Pharmacol. 28: 475-477.
Hoffmann RM, Schwarz G, Pohl C, Ziegenhagen DJ, Kruis W 2005 Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility. Dtsch. Med. Wochenschr. 130: 1938-1943.
Hofmann AF 1999 The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159: 2647-2658. *
Hofmann AF 1999 Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14: 24-29. *
Hofmann AF 1995 Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol. 27: 106-113.
Hofmann AF 1998 Progress in idiopathic bile acid malabsorption. Gut 43: 738-739. *
Hofmann AF, Hagey LR 2008 Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65: 2461-2483.
Houten S, Auwerx J 2004 The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36: 482-491.
Houten SM, Watanabe M, Auwerx J 2006 Endocrine functions of bile acids. EMBO J. 25: 1419-1425. *
Howard PJ, Murphy GM 2003 Bile acid stress in the mother and baby unit. Eur. J. Gastroenterol. Hepatol. 15: 317-321.
Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, Li S, Gao H, Ryan TP, Michael MD, Michael LF 2006 Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J. Biol. Chem. 281: 39831-39838. *
Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Pelaez F, Wright SD, Cui J 2003 Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278: 51085-51090. *
Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, Mozell RL, Byrnes JJ, Stricker-Krongrad A, Chou CJ, Tartaglia LA, Lodish HF, Stahl A, Gimeno RE 2006 Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130: 1259-1269. *
Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC 2002 Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290: 35-43. *
Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, Peeters PM, Sauer PJ, Verkade HJ 2004 Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl. 10: 872-880. *
Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gafvels M, Einarsson C, Alexson SE 2000 The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 275: 28947-28953. *
Hunter RJ, Patel VB, Baker AJ, Preedy VR 2004 Liver dysfunction induced by bile duct ligation and galactosamine injection alters cardiac protein synthesis. Metabolism 53: 964-968. *
Hylemon PB, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Pandak WM, Dent P 2006 Conjugated bile acids promote activation of the ERK 1/2 and AKT pathways via a pertussis toxin-sensitive GI-dependent mechanism in primary rodent and human hepatocytes. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 24. *
Hyogo H, Tazuma S, Cohen DE 2002 Cholesterol gallstones. Curr. Opin. Gastroenterol. 18: 366-371.
Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, Tanaka N 2005 Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A(2) expression in HepG2 cells. Hepatology 41: 896-905. *
Inoue Y, Yu AM, Inoue J, Gonzalez FJ 2004 Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J. Biol. Chem. 279: 2480-2489. *
Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Björkhem I, Gonzalez FJ 2006 Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J. Lipid Res. 47: 215-227. *
Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O'Connell NC, Podda M 1999 Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 29: 320-327. *
Ishizaki K, Imada T, Tsurufuji M 2005 Hepatoprotective bile acid 'ursodeoxycholic acid (UDCA)' property and difference as bile acids. Hepatol. Res. 33: 174-177.
Jacquemin E 1999 Progressive familial intrahepatic cholestasis. J. Gastroenterol. Hepatol. 14: 594-599.
Jacquemin E, Dumont M, Bernard O, Erlinger S, Hadchouel M 1994 Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease). Eur. J. Pediatr. 153: 424-428.
Jansen GR 1999 Effect of delta(22)-5beta-taurocholenic acid on hepatic cholesterol and fatty acid in gold thioglucose obese mice fed low- or high-fat diets. J. Nutr. Biochem. 10: 638-643.
Jansen PL, Sturm E 2003 Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322. *
Javitt NB 2002 Cholesterol, hydroxycholesterols, and bile acids. Biochem. Biophys. Res. Commun. 292: 1147-1153. *
Javitt NB 1977 Diagnostic value of serum bile acids. Clin. Gastroenterol. 6: 219-226.
Javitt NB 1990 26-Hydroxycholesterol: synthesis, metabolism, and biologic activities. J. Lipid Res. 31: 1527-1533. *
Javitt NB 1990 Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J. 4: 161-168. *
Javitt NB, Budai K 1989 Cholesterol and bile acid synthesis in Hep G2 cells. Metabolic effects of 26- and 7 alpha-hydroxycholesterol. Biochem. J. 262: 989-992. *
Javitt NB, Kok E, Carubbi F, Blizzard T, Gut M, Byon CY 1986 Bile acid synthesis. Metabolism of 3 beta-hydroxy-5-cholenoic acid to chenodeoxycholic acid. J. Biol. Chem. 261: 12486-12489. *
Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M 2007 Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56: 2485-2493.
Jiang W, Miyamoto T, Kakizawa T, Nishio SI, Oiwa A, Takeda T, Suzuki S, Hashizume K 2006 Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem. Biophys. Res. Commun. 351: 176-184. *
Jiang ZY, Parini P, Eggertsen G, Davis MA, Hu H, Suo GJ, Zhang SD, Rudel LL, Han TQ, Einarsson C 2008 Increased expression of LXRalpha , ABCG5, ABCG8 and SRBI in the liver from normolipidemic nonobese Chinese gallstone patients. J. Lipid Res. 49: 464-472. *
Jones EA, Bergasa NV 1999 The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur. J. Gastroenterol. Hepatol. 11: 623-631.
Jonkers IJ, Smelt AH, Princen HM, Kuipers F, Romijn JA, Boverhof R, Masclee AA, Stellaard F 2006 Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J. Nutr. 136: 987-991. *
Joplin R, Lindsay JG, Hubscher SG, Johnson GD, Shaw JC, Strain AJ, Neuberger JM 1991 Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study. Hepatology 14: 442-447.
Jourdan M, Vaubourdolle M, Cynober L, Aussel C 2004 Effect of aging on liver functions-an experimental study in a perfused rat liver model. Exp. Gerontol. 39: 1341-1346.
Jump DB 2002 Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 13: 155-164.
Jung D, Elferink MG, Stellaard F, Groothuis GM 2007 Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27: 137-144. *
Jung D, Fried M, Kullak-Ublick GA 2002 Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277: 30559-30566. *
Juppner H, Rittinghaus EF, Ahlgrimm M, Burdelski M, Dralle H 1986 C-terminal PTH (70-84) after biliary ligation in rats: implications for the diagnostic importance in hepatobiliary disease. Biochem. Biophys. Res. Commun. 139: 633-636.
Kaeding J, Bouchaert E, Belanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Belanger A, Barbier O 2008 Activators of the farnesoid X-receptor negatively regulate androgen glucuronidation in human prostate cancer LNCaP cells. Biochem. J. 410: 245-253. *
Kahn E 2004 Biliary atresia revisited. Pediatr. Dev. Pathol. 7: 109-124.
Kalaany NY, Mangelsdorf DJ 2006 LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68: 159-191. *
Kamath AV, Chong S, Chang M, Marathe PH 2005 P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother. Pharmacol. 55: 110-116. *
Kamisako T, Ogawa H 2005 Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J. Gastroenterol. Hepatol. 20: 1429-1434. *
Kamisako T, Ogawa H 2003 Effect of obstructive jaundice on the regulation of hepatic cholesterol metabolism in the rat. Disappearance of abcg5 and abcg8 mRNA after bile duct ligation. Hepatol. Res. 25: 99-104.
Kamisako T, Ogawa H, Yamamoto K 2007 Effect of cholesterol, cholic acid and cholestyramine administration on the intestinal mRNA expressions related to cholesterol and bile acid metabolism in the rat. J. Gastroenterol. Hepatol. 22: 1832-1837. *
Kanayama T, Arito M, So K, Hachimura S, Inoue J, Sato R 2007 Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J. Biol. Chem. 282: 10290-10298. *
Kannenberg F, Ellinghaus P, Assmann G, Seedorf U 1999 Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. J. Biol. Chem. 274: 35455-35460. *
Kaplan MM 2004 Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am. J. Gastroenterol. 99: 2147-2149. *
Karlsen TH, Boberg KM, Schrumpf E 2006 Role of polymorphisms in genes involved in bile acid detoxification pathways in primary sclerosing cholangitis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 87. *
Keizman D, Goldiner I, Leikin-Frenkel A, Konikoff FM 2008 Innovations in the medical treatment of gallstones and fatty liver: FABACs (fatty acid bile acid conjugates). Harefuah. 147: 344-349, 373, 372.
Kemper JK, Kim H, Miao J, Bhalla S, Bae Y 2004 Role of an mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP. Mol. Cell. Biol. 24: 7707-7719. *
Keppler D, Konig J, Buchler M 1997 The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv. Enzyme Regul. 37: 321-333. *
Kershenobich D, Antonio Alanis J, Fe Bornstein M, Perez Herrera M, Alvarado Ramos E, Irene Suarez G 1978 Endotoxins and liver. Rev. Gastroenterol. Mex. 43: 49-57.
Kesaniemi YA, Miettinen TA, Salaspuro MP 1981 Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes. Gut 22: 579-584. *
Khan SA, Jane Cox I, Thillainayagam AV, Bansi DS, Thomas HC, Taylor-Robinson SD 2005 Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur. J. Gastroenterol. Hepatol. 17: 733-738.
Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C 2004 Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196. *
Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR 2004 Suppression of DHEA sulfotransferase (Sult2A1) during the acute phase response. Am. J. Physiol. Endocrinol. Metab. 287: E731-E738. *
Kim MS, Sweeney 1 TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR 2007 Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism 56: 267-279. *
Kirkpatrick RB, Killenberg PG 1980 Effects of ethinylestradiol on enzymes catalyzing bile acid conjugation and sulfation. J. Lipid Res. 21: 895-901. *
Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T 2002 Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am. J. Gastroenterol. 97: 1849-1851. *
Kiyosawa N, Ito K, Niino N, Sakuma K, Kanbori M, Yamoto T, Manabe S, Matsunuma N 2004 Effect of serum cholesterol on the mRNA content of amyloid precursor protein in rat livers. Toxicol. Lett. 150: 157-166. *
Klaassen CD, Lu H 2008 Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101: 186-196. *
Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S 2005 NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis. Hepatology 43: 126-133. *
Kliewer SA, Goodwin B, Willson TM 2002 The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23: 687-702. *
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM 1992 Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774. *
Kliewer SA, Willson TM 2002 Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res. 43: 359-364. *
Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F 2003 Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124: 160-171. *
Kondrackiene J, Beuers U, Kupcinskas L 2005 Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901. *
Konikoff FM, Leikin-Frenkel A, Goldiner I, Michowitz M, Brezowski E, Harats D, Gilat T 2003 Biliary and systemic effects of fatty acid bile acid conjugates. Eur. J. Gastroenterol. Hepatol. 15: 649-655.
Koopen NR, Wolters H, Havinga R, Vonk RJ, Jansen PL, Muller M, Kuipers F 1998 Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 27: 537-545. *
Koopman BJ, Wolthers BG, van der Molen JC, Nagel GT, Kruizinga W 1987 Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid. Biochim. Biophys. Acta 917: 238-246.
Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Kubik R, Hanson J, Urda E, Mutlib AE 2006 Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90: 451-459. *
Kowdley KV 1998 Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin. Liver Dis. 2: 373-389, x.
Krahenbuhl S, Fischer S, Talos C, Reichen J 1994 Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 20: 1595-1601.
Krahenbuhl S, Krahenbuhl-Glauser S, Stucki J, Gehr P, Reichen J 1992 Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. Hepatology 15: 1167-1172.
Kramer W, Glombik H 2006 Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13: 997-1016.
Krasowski MD, Yasuda K, Hagey LR, Schuetz EG 2005 Evolution of the pregnane X receptor: adaptation to cross-species differences in biliary bile salts. Mol. Endocrinol. 19: 1720-1739. *
Kreeft AJ, Moen CJ, Porter G, Kasanmoentalib S, Sverdlov R, van Gorp PJ, Havekes LM, Frants RR, Hofker MH 2005 Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. Atherosclerosis 182: 249-257.
Kretschmer NW, Boor PJ, el Azhary RA, Ahmed AE, Reynolds ES 1987 Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. III. Ultrastructural characterization of bile duct injury. Cancer Chemother. Pharmacol. 19: 109-117.
Kretschmer XC, Baldwin WS 2005 CAR and PXR: xenosensors of endocrine disrupters? Chem. Biol. Interact. 155: 111-128. *
Krisans SK, Thompson SL, Pena LA, Kok E, Javitt NB 1985 Bile acid synthesis in rat liver peroxisomes: metabolism of 26-hydroxycholesterol to 3 beta-hydroxy-5-cholenoic acid. J. Lipid Res. 26: 1324-1332. *
Kubitz R, Keitel V, Burdelski M, Haussinger D 2006 Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35. *
Kudo A, Kashiwagi S, Kajimura M, Yoshimura Y, Uchida K, Arii S, Suematsu M 2004 Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. Hepatology 39: 1099-1109. *
Kuipers F, Claudel T, Sturm E, Staels B 2004 The farnesoid X receptor (FXR) as modulator of bile acid metabolism. Rev. Endocr. Metab. Disord. 5: 319-326. *
Kuipers F, Stroeve JH, Caron S, Staels B 2007 Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr. Opin. Lipidol. 18: 289-297.
Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M 2001 Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am. J. Gastroenterol. 96: 3110-3116. *
Kullak-Ublick GA 2006 Regulation of hepatic and intestinal bile acid transport by FXR controlled signaling pathways. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 51-52. *
Kullak-Ublick GA, Beuers U, Paumgartner G 2000 Hepatobiliary transport. J. Hepatol. 32: S3-S18.
Kumagai M, Kimura A, Takei H, Kurosawa T, Aoki K, Inokuchi T, Matsuishi T 2007 Perinatal bile acid metabolism: bile acid analysis of meconium of preterm and full-term infants. J. Gastroenterol. 42: 904-910. *
Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M 2007 Tissue-specific expression of beta KLOTHO and fibroblast growth factor receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282: 26687-26695. *
Kuver R, Savard CE, Lee SK, Haigh WG, Lee SP 2007 Murine gallbladder epithelial cells can differentiate into hepatocyte-like cells in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G944-G955. *
Lacaille F 1995 Bile acids and their therapeutic use in children. Arch. Pediatr. 2: 1200-1208.
Lam NV, Chen W, Suruga K, Nishimura N, Goda T, Yokogoshi H 2006 Enhancing effect of taurine on CYP7A1 mRNA expression in Hep G2 cells. Amino Acids 30: 43-48. *
Lammert F, Marschall HU, Matern S 2003 Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132.
Landrier JF, Malezet-Desmoulins C, Reboul E, Marie Lorec A, Josephe Amiot M, Borel P 2008 Comparison of different vehicles to study the effect of tocopherols on gene expression in intestinal cells. Free Radic. Res. 42: 523-530.
Lazaridis KN, Lindor KD 1999 Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480.
Leclerc D, Rozen R 2007 Molecular genetics of MTHFR: polymorphisms are not all benign. Med. Sci. (Paris) 23: 297-302.
Lee C, Martin KO, Javitt NB 1996 Bile acid synthesis: 7 alpha-hydroxylation of intermediates in the sterol 27-hydroxylase metabolic pathway. J. Lipid Res. 37: 1356-1362. *
Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y 2006 FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31: 572-580. *
Lee H, Hubbert ML, Osborne TF, Woodford K, Zerangue N, Edwards PA 2007 Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha. J. Biol. Chem. 282: 21653-21661. *
Lee JY, Jung da W, Park HA, Kim SJ, Chung JH, Moon CK, Kim YC 2004 Effect of taurine on biliary excretion and metabolism of acetaminophen in male hamsters. Biol. Pharm. Bull. 27: 1792-1796. *
Lee YK, Moore DD 2002 Dual mechanisms for repression of the monomeric orphan receptor liver receptor homologous protein-1 by the orphan small heterodimer partner. J. Biol. Chem. 277: 2463-2467. *
Lefkowitch JH 2007 Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231.
Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U 1999 Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117: 918-925. *
Levy C, Lindor KD 2003 Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498.
Levy C, Lindor KD 2003 Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103.
Levy E, Brunet S, Alvarez F, Seidman E, Bouchard G, Escobar E, Martin S 2007 Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. Life Sci. 80: 1472-1483. *
Lewis GF 2006 Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr. Opin. Cardiol. 21: 345-352.
Lewis S, Cochrane S 2007 Alteration of sulfate and hydrogen metabolism in the human colon by changing intestinal transit rate. Am. J. Gastroenterol. 102: 624-633. *
Li J, Pircher PC, Schulman IG, Westin SK 2005 Regulation of complement C3 expression by the bile acid receptor FXR. J. Biol. Chem. 280: 7427-7434. *
Li S, Zhang ZW, Guan YF 2003 On the bile acid receptor FXR. Sheng Li Ke Xue Jin Zhan 34: 314-318.
Li T, Chen W, Chiang JY 2007 PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 48: 373-384. *
Li T, Chiang JY 2005 Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G74-G84. *
Li Y, Mezei O, Shay NF 2007 Human and murine hepatic sterol-12-alpha-hydroxylase and other xenobiotic metabolism mRNA are upregulated by soy isoflavones. J. Nutr. 137: 1705-1712. *
Li-Hawkins J, Gafvels M, Olin M, Lund EG, Andersson U, Schuster G, Bjorkhem I, Russell DW, Eggertsen G 2002 Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Invest. 110: 1191-1200. *
Li-Hawkins J, Lund EG, Bronson AD, Russell DW 2000 Expression cloning of an oxysterol 7alpha-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275: 16543-16549. *
Li-Hawkins J, Lund EG, Turley SD, Russell DW 2000 Disruption of the oxysterol 7alpha-hydroxylase gene in mice. J. Biol. Chem. 275: 16536-16542. *
Liang CP, Tall AR 2001 Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276: 49066-49076. *
Liddle C, Goodwin B 2002 Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. Semin. Liver Dis. 22: 115-122.
Lillienau J, Crombie DL, Munoz J, Longmire-Cook SJ, Hagey LR, Hofmann AF 1993 Negative feedback regulation of the ileal bile acid transport system in rodents. Gastroenterology 104: 38-46.
Lin Y, Dueker SR, Follett JR, Fadel JG, Arjomand A, Schneider PD, Miller JW, Green R, Buchholz BA, Vogel JS, Phair RD, Clifford AJ 2004 Quantitation of in vivo human folate metabolism. Am. J. Clin. Nutr. 80: 680-691. *
Lindblad A, Glaumann H, Strandvik B 1998 A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 27: 166-174. *
Ling V, Lam P, Forrest D, Liu L, Wang R 2004 Bile acid transport in Spgp (BSEP) knockout mice. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 37. June 18-19. *
Liscovitch M, Lavie Y 2002 Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 1-7. *
Liu Y, Havinga R, van der Leij FR, Boverhof R, Sauer PJ, Kuipers F, Stellaard F 2008 Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. Pediatr. Res. 63: 375-381.
Los EL, Wolters H, Stellaard F, Kuipers F, Verkade HJ, Rings EH 2007 Intestinal capacity to digest and absorb carbohydrates is maintained in a rat model of cholestasis. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G615-G622. *
Lou G, Li Y, Chen B, Chen M, Chen J, Liao R, Zhang Y, Wang Y, Zhou D 2007 Functional analysis on the 5'-flanking region of human FXR gene in HepG2 cells. Gene 396: 358-368. *
Love MW, Craddock AL, Angelin B, Brunzell JD, Duane WC, Dawson PA 2001 Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21: 2039-2045. *
Lovisetto P, Raviolo P 1994 Intrahepatic cholestasis caused by biochemical errors of bile acids. Part I - Nosographic, pathogenetic, diagnostic features. Minerva Med. 85: 589-596.
Lovisetto P, Raviolo P 1994 Intrahepatic cholestasis due to biochemical errors of bile acids. II. Clinical and therapeutic aspects. Minerva. Med. 85: 639-646.
Lundasen T, Andersson EM, Schreyer S, Ostlund-Lindqvist AM, Angelin B, Rudling M 2006 Ileal bile acid transport inhibition lowers plasma glucose and lipid levels in ob/ob mice. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 45. *
Lundell K, Wikvall K 2008 Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9: 323-331.
Ma K, Saha PK, Chan L, Moore DD 2006 Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116: 1102-1109. *
Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD 2006 Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem. Pharmacol. 72: 512-522. *
Makishima M 2005 Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 97: 177-183. *
Makowski P, Pikula S 1997 Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394.
Mandard S, Muller M, Kersten S 2004 Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. Life Sci. 61: 393-416. *
Mano Y, Usui T, Kamimura H 2006 Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos. 28: 13-18. *
Marin JJG, Romero MR, Vallejo M, Perez MJ, Briz O 2005 Emerging interest in bile acid transporters in pathophysiology and pharmacology. Med. Hypotheses Res. 2: 425-448. *
Markovich D 2006 Sulfate transport by SLC26 transporters. Novartis Found. Symp. 273: 42-51.
Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M 2005 Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485. *
Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F 2005 Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560. *
Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F 2006 Liver fatty acid binding protein (L-FABP) gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G36-G48. *
Martinez LO, Jacquet S, Terce F, Collet X, Perret B, Barbaras R 2004 New insight on the molecular mechanisms of high-density lipoprotein cellular interactions. Cell. Mol. Life Sci. 61: 2343-2360. *
Masson D, Lagrost L, Athias A, Gambert P, Brimer-Cline C, Lan L, Schuetz JD, Schuetz EG, Assem M 2005 Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 25: 2164-2169. *
Masson D, Qatanani M, Sberna AL, Xiao R, Pais de Barros JP, Grober J, Deckert V, Athias A, Gambert P, Lagrost L, Moore DD, Assem M 2008 Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J. Lipid Res. 49: 1682-1691. *
Mataki C, Magnier BC, Houten SM, Annicotte JS, Argmann C, Thomas C, Overmars H, Kulik W, Metzger D, Auwerx J, Schoonjans K 2007 Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol. Cell Biol. 27: 8330-8339. *
Mato JM, Martinez-Chantar ML, Lu SC 2008 Methionine metabolism and liver disease. Annu. Rev. Nutr. 28: 273-293. *
Mazumder I, Mahato SB 1993 Bile acid transformations by Alcaligenes recti. Steroids 58: 79-86.
Mazzella G, Fusaroli P, Pezzoli A, Azzaroli F, Mazzeo C, Zambonin L, Simoni P, Festi D, Roda E 1999 Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. Dig. Dis. Sci. 44: 2478-2483. *
Mazzella G, Parini P, Bazzoli F, Villanova N, Festi D, Aldini R, Roda A, Cipolla A, Polimeni C, Tonelli D, et al 1993 Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig. Dis. Sci. 38: 896-902.
Mazzella G, Rizzo N, Azzaroli F, Simoni P, Bovicelli L, Miracolo A, Simonazzi G, Colecchia A, Nigro G, Mwangemi C, Festi D, Roda E 2001 Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 33: 504-508. *
McCarthy TC, Li X, Sinal CJ 2005 Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein-3 gene expression by bile acids. J. Biol. Chem. 280: 23232-23242. *
McGarr SE, Ridlon JM, Hylemon PB 2005 Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J. Clin. Gastroenterol. 39: 98-109.
McNeil CJ, Hay SM, Rucklidge GJ, Reid M, Duncan G, Maloney CA, Rees WD 2008 Disruption of lipid metabolism in the liver of the pregnant rat fed folate-deficient and methyl donor-deficient diets. Br. J. Nutr. 99: 262-271. *
Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A, Brodehl J 2000 Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am. J. Gastroenterol. 95: 3522-3528. *
Mendez-Sanchez N, Panduro A, Murguia D, Rincon AR, Uribe M 2002 Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann. Hepatol. 1: 85-89. *
Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjovall J 1997 Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J. Hepatol. 27: 1029-1040. *
Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjovall J 1997 Profiles of bile acids and progesterone metabolites in the urine and serum of women with intrahepatic cholestasis of pregnancy. J. Hepatol. 27: 346-357. *
Miao J, Fang S, Bae Y, Kemper JK 2006 Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J. Biol. Chem. 281: 14537-14546. *
Michaels A, Levy C 2008 The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61.
Mieli-Vergani G, Vergani D 2004 Liver transplantation in metabolic liver diseases. J. Gastroenterol. Hepatol. 19: S396-S397. *
Miettinen TE, Tarpila S, Gylling H 1997 The effects of ursodeoxycholic acid on serum and biliary noncholesterol sterols in patients with gallstones. Hepatology 25: 514-518. *
Miyata M, Watase H, Hori W, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y 2006 Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity. Xenobiotica 36: 631-644. *
Modica S, Moschetta A 2006 Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett. 580: 5492-5499. *
Mohan R, Heyman RA 2003 Orphan nuclear receptor modulators. Curr. Top. Med. Chem. 3: 1637-1647.
Monte MJ, Fernandez-Tagarro M, Macias RI, Jimenez F, Gonzalez-San Martin F, Marin JJ 2005 Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin. Sci. (Lond.) 109: 199-207. *
Moore JT, Goodwin B, Willson TM, Kliewer SA 2002 Nuclear receptor regulation of genes involved in bile acid metabolism. Crit. Rev. Eukaryot. Gene Expr. 12: 119-135.
Moran JM, Salas J, Botello F, Macia E, Climent V 2005 Taurine and cholestasis associated to TPN. Experimental study in rabbit model. Pediatr. Surg. Int. 21: 786-792.
Moreno M, Molina H, Amigo L, Zanlungo S, Arrese M, Rigotti A, Miquel JF 2003 Hepatic overexpression of caveolins increases bile salt secretion in mice. Hepatology 38: 1477-1488. *
Moschetta A, Kliewer SA 2005 Weaving betaKlotho into bile acid metabolism. J. Clin. Invest. 115: 2075-2077. *
Motojima K 2004 17beta-Hydroxysteroid dehydrogenase type 11 is a major peroxisome proliferator-activated receptor alpha-regulated gene in mouse intestine. Eur. J. Biochem. 271: 4141-4146. *
Moustafa MA, Ogino D, Nishimura M, Ueda N, Naito S, Furukawa M, Uchida T, Ikai I, Sawada H, Fukumoto M 2004 Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci. 95: 530-536. *
Murakami T, Walczak R, Caron S, Duhem C, Vidal V, Darteil R, Staels B 2007 The farnesoid X receptor induces fetuin-B gene expression in human hepatocytes. Biochem. J. 407: 461-469. *
Nagasaka H, Miida T, Hirano KI, Ota A, Murayama K, Yorifuji T, Kobayashi K, Takatani T, Tsukahara H, Hui SP, Takayanagi M, Chiba H 2008 Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome. Atherosclerosis 198: 434-440.
Nakagaki M, Danzinger RG, Hofmann AF, DiPietro RA 1984 Biliary secretion and hepatic metabolism of taurine-conjugated 7 alpha-hydroxy and 7 beta-hydroxy bile acids in the dog. Defective hepatic transport and bile hyposecretion. Gastroenterology 87: 647-659.
Nakahara M, Fujii H, Maloney PR, Shimizu M, Sato R 2002 Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J. Biol. Chem. 277: 37229-37234. *
Nakamoto K, Wang S, Jenison RD, Guo GL, Klaassen CD, Wan YJ, Zhong XB 2006 Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet. 7: 29. *
Nakamura K, Aoshima M, Tani M, Kato T, Fugita M, Kimura A, Hasegawa T, Akiyama K, Makino I 1992 Effect of ursodeoxycholic acid (UDCA) therapy for compensatory liver cirrhosis on liver function tests and serum bile acid metabolism. Nippon Shokakibyo Gakkai Zasshi 89: 2762-2770.
Nakashima T, Sano A, Seto Y, Nakajima T, Shima T, Sakamoto Y, Okuno T, Kashima K, Hasegawa T 1990 Unusual trihydroxy bile acids in the urine of patients treated with chenodeoxycholate, ursodeoxycholate or rifampicin and those with cirrhosis. Hepatology 11: 255-260.
Nakashima T, Yoh T, Sumida Y, Kakisaka Y, Mitsuyoshi H 2001 Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis. J. Gastroenterol. Hepatol. 16: 541-547. *
Newton DJ, Wang RW, Evans DC 2005 Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR(-) and EHBR rats. Life Sci. 77: 1106-1115. *
Nguyen A, Bouscarel B 2008 Bile acids and signal transduction: role in glucose homeostasis. Cell. Signal. Jun 27 [Epub ahead of print]. *
Nilsell K, Angelin B, Leijd B, Einarsson K 1983 Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 85: 1248-1256.
Nishioka T, Hyogo H, Numata Y, Yamaguchi A, Kobuke T, Komichi D, Nonaka M, Inoue M, Nabeshima Y, Ogi M, Iwamoto K, Ishitobi T, Ajima T, Chayama K, Tazuma S 2005 A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. J. Atheroscler. Thromb. 12: 211-217. *
Nojiri S, Nakao H, Sugauchi F, Miyaki T, Senda K, Sasaki M, Kataoka H, Kamiya T, Nakazawa T, Ohara H, Orito E, Joh T 2008 Effect of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis C virus infection. Hepatol. Res. Aug 19 [Epub ahead of print]. *
Nolan DG, Martin LS, Natarajan S, Hume RF Jr 1994 Fetal compromise associated with extreme fetal bile acidemia and maternal primary sclerosing cholangitis. Obstet. Gynecol. 84: 695-696.
Nomiyama T, Bruemmer D 2008 Liver X receptors as therapeutic targets in metabolism and atherosclerosis. Curr. Atheroscler. Rep. 10: 88-95.
Norata GD, Catapano AL 2004 Lipid lowering activity of drugs affecting cholesterol absorption. Nutr. Metab. Cardiovasc. Dis. 14: 42-51.
Ohashi K, Yokoyama T, Yamato M, Kuge H, Kanehiro H, Tsutsumi M, Amanuma T, Iwata H, Yang J, Okano T, Nakajima Y 2007 Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat. Med. 13: 880-885. *
Ohno M 2008 Functional analysis of nuclear receptor FXR controlling metabolism of cholesterol. Yakugaku Zasshi 128: 343-355. *
Ohta Y, Kongo-Nishimura M, Imai Y, Kitagawa A 2007 Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment. J. Pineal Res. 42: 159-165. *
Okuda H, Obata H, Nakanishi T, Hisamitsu T, Matsubara K, Watanabe H 1984 Quantification of individual serum bile acids in patients with liver diseases using high-performance liquid chromatography. Hepatogastroenterology 31: 168-171.
Ory DS 2004 Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ. Res. 95: 660-670. *
Oshima H, Kon J, Ooe H, Hirata K, Mitaka T 2008 Functional expression of organic anion transporters in hepatic organoids reconstructed by rat small hepatocytes. J. Cell. Biochem. 104: 68-81. *
Palermo M, Marazzi MG, Hughes BA, Stewart PM, Clayton PT, Shackleton CH 2008 Human delta(4)-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 73: 417-423.
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ, Maurel P 2004 Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34: 633-664.
Pascussi JM, Vilarem MJ 2008 Molecular mechanisms linking xenobiotic metabolism and inflammation. Med. Sci. (Paris) 24: 301-305.
Patel DD, Knight BL, Soutar AK, Gibbons GF, Wade DP 2000 The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochem. J. 351: 747-753. *
Paumgartner G 2006 Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J. Gastroenterol. 12: 4445-4451. *
Pawar A, Botolin D, Mangelsdorf DJ, Jump DB 2003 The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression. J. Biol. Chem. 278: 40736-40743. *
Pawlikowska L, Groen A, Eppens EF, Kunne C, Ottenhoff R, Looije N, Knisely AS, Killeen NP, Bull LN, Oude Elferink RP, Freimer NB 2004 A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 13: 881-892. *
Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ 1998 Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693-704. *
Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B 2003 Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17: 259-272. *
Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK 2003 Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278: 27703-27711. *
Plosch T, Bloks VW, Terasawa Y, Berdy S, Siegler K, Van Der Sluijs F, Kema IP, Groen AK, Shan B, Kuipers F, Schwarz M, Schwartz M 2004 Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. Gastroenterology 126: 290-300. *
Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP 2005 Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16. *
Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM 2001 Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21: 1840-1845. *
Post SM, Groenendijk M, van der Hoogt CC, Fievet C, Luc G, Hoekstra M, Princen HM, Staels B, Rensen PC 2006 Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 26: 2724-2730.
Poupon R 2003 Molecular mechanisms of bile formation and cholestatic diseases. Bull. Acad. Natl. Med. 187: 1261-1274.
Poupon RE, Ouguerram K, Chretien Y, Verneau C, Eschwege E, Magot T, Poupon R 1993 Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 17: 577-582.
Prall RT, Lindor KD, Wiesner RH, LaRusso NF 2000 Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103.
Purucker E, Marschall HU, Winograd R, Matern S 2001 Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Biochim. Biophys. Acta 1526: 44-52. *
Rader DJ 2007 Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol. 100: S15-S19. *
Raedsch R, Lauterburg BH, Hofmann AF 1981 Altered bile acid metabolism in primary biliary cirrhosis. Dig. Dis. Sci. 26: 394-401.
Raicht RF, Cohen BI, Sarwal A, Takahashi M 1978 Ursodeoxycholic acid. Effects on sterol metabolism in rats. Biochim. Biophys. Acta 531: 1-8.
Raunio H, Hakkola J, Pelkonen O 2005 Regulation of CYP3A genes in the human respiratory tract. Chem. Biol. Interact. 151: 53-62. *
Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH 1993 The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur. Heart J. 14 Suppl. K: 125-129.
Reddy JK, Hashimoto T 2001 Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21: 193-230. *
Redinger RN 2003 The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: bile salts as ligands for nuclear hormone receptors. Can. J. Gastroenterol. 17: 265-271.
Redinger RN 2003 Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis. J. Lab. Clin. Med. 142: 7-20. *
Repa JJ, Mangelsdorf DJ 2000 The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16: 459-481. *
Repa JJ, Mangelsdorf DJ 1999 Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10: 557-563.
Reyes H, Simon FR 1993 Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin. Liver Dis. 13: 289-301.
Reyes H, Sjovall J 2000 Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32: 94-106.
Rieger R, Oertelt S, Selmi C, Invernizzi P, Podda M, Gershwin ME 2005 Decreased serum leptin levels in primary biliary cirrhosis: a link between metabolism and autoimmunity? Ann. N. Y. Acad. Sci. 1051: 211-217. *
Rifai K, Hafer C, Rosenau J, Thmann CA, Haller H, Manns MP, Fliser D 2006 Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand. J. Gastroenterol. 41: 1212-1217. *
Rodrigues CM, Kren BT, Steer CJ, Setchell KD 1996 Formation of delta 22-bile acids in rats is not gender specific and occurs in the peroxisome. J. Lipid Res. 37: 540-550. *
Rodriguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J 2002 Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 50: 701-706. *
Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM 2004 Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59: 855-861. *
Rogler G 2006 Significance of anti-inflammatory effects of PPARgamma agonists? Gut 55: 1067-1069. *
Roy CC, Weber AM, Morin CL, Lepage G, Brisson G, Yousef I, Lasalle R 1982 Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J. Pediatr. Gastroenterol. Nutr. 1: 469-478.
Rudling M, Parini P, Angelin B 1997 Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat. J. Clin. Invest. 99: 2239-2245. *
Ruiz ML, M Villanueva SS, Luquita MG, Sanchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, Catania VA 2005 Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem. Pharmacol. 69: 531-539. *
Rutgeerts P, Ghoos Y, Vantrappen G 1982 Kinetics of primary bile acids in patients with non-operated Crohn's disease. Eur. J. Clin. Invest. 12: 135-143.
Sanchez-Mete L, Attili AF 2000 Cholelithiasis: genetic hypothesis. Minerva Gastroenterol. Dietol. 46: 45-55.
Sandhu BS, Luketic VA 2006 Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849. *
Sanyal S, Bavner A, Haroniti A, Nilsson LM, Lundasen T, Rehnmark S, Witt MR, Einarsson C, Talianidis I, Gustafsson JA, Treuter E 2007 Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 104: 15665-15670. *
Sato M, Sato K, Furuse M 2008 Change in hepatic and plasma bile acid contents and its regulatory gene expression in the chicken embryo. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 150: 344-347. *
Sauer P, Kloters-Plachky P, Stiehl A 1995 Inhibition of ileal bile acid transport by cyclosporin A in rat. Eur. J. Clin. Invest. 25: 677-682.
Sauer P, Rudolph G, Endele R, Senn M, Theilmann L, Otto G, Stremmel W, Stiehl A 1996 Kinetics of primary bile acids in patients after orthotopic liver transplantation. Eur. J. Clin. Invest. 26: 979-982.
Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP 2005 Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Pharmacol. Exp. Ther. 312: 170-178. *
Schaffner F 2000 The history of liver disease at The Mount Sinai Hospital. Mt. Sinai J. Med. 67: 76-83. *
Schliess F, Haussinger D 2007 Osmosensing by integrins in rat liver. Methods Enzymol. 428: 129-144.
Schlosser PM, Borghoff SJ, Coldham NG, David JA, Ghosh SK 2006 Physiologically-based pharmacokinetic modeling of genistein in rats, part I: model development. Risk Anal. 26: 483-500. *
Schmassmann A, Angellotti MA, Clerici C, Hofmann AF, Ton-Nu HT, Schteingart CD, Marcus SN, Hagey LR, Rossi SS, Aigner A 1990 Transport, metabolism, and effect of chronic feeding of lagodeoxycholic acid. A new, natural bile acid. Gastroenterology 99: 1092-1104.
Schmassmann A, Fehr HF, Locher J, Lillienau J, Schteingart CD, Rossi SS, Hofmann AF 1993 Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology 104: 1171-1181.
Schmuth M, Elias PM, Feingold KR 2003 Beyond glucocorticoids, retinoids and vitamin D - the evolution of nuclear hormone type transcription factor targeting in the skin. J. Dtsch. Dermatol. Ges. 1: 352-362.
Schreibman I, Regev A 2006 Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30.
Schuppan D, Jia JD, Brinkhaus B, Hahn EG 1999 Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104. *
Schwarz M, Lund EG, Lathe R, Bjorkhem I, Russell DW 1997 Identification and characterization of a mouse oxysterol 7alpha-hydroxylase cDNA. J. Biol. Chem. 272: 23995-24001. *
Schwarz M, Lund EG, Setchell KD, Kayden HJ, Zerwekh JE, Bjorkhem I, Herz J, Russell DW 1996 Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase. J. Biol. Chem. 271: 18024-18031. *
Schwarz M, Russell DW, Dietschy JM, Turley SD 1998 Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 39: 1833-1843. *
Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW 2000 The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J. Clin. Invest. 106: 1175-1184. *
Scotti E, Gilardi F, Godio C, Gers E, Krneta J, Mitro N, De Fabiani E, Caruso D, Crestani M 2007 Bile acids and their signaling pathways: eclectic regulators of diverse cellular functions. Cell. Mol. Life Sci. 64: 2477-2491. *
Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Yueh MF, Bonzo JA, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, Barbier OK, Tukey RH 2007 Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab. Dispos. 35: 419-427. *
Seo YK, Chung YT, Kim S, Echchgadda I, Song CS, Chatterjee B 2007 Xenobiotic- and vitamin D-responsive induction of the steroid/bile acid-sulfotransferase Sult2A1 in young and old mice: the role of a gene enhancer in the liver chromatin. Gene 386: 218-223. *
Setchell KD, Heubi JE, Bove KE, O'Connell NC, Brewsaugh T, Steinberg SJ, Moser A, Squires RH Jr 2003 Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 124: 217-232. *
Setchell KD, Yamashita H, Rodrigues CM, O'Connell NC, Kren BT, Steer CJ 1995 delta 22-Ursodeoxycholic acid, a unique metabolite of administered ursodeoxycholic acid in rats, indicating partial beta-oxidation as a major pathway for bile acid metabolism. Biochemistry 34: 4169-4178.
Shafqat N, Marschall HU, Filling C, Nordling E, Wu XQ, Bjork L, Thyberg J, Martensson E, Salim S, Jornvall H, Oppermann U 2003 Expanded substrate screenings of human and Drosophila type 10 17beta-hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism. Biochem. J. 376: 49-60. *
Shefer S, Zaki FG, Salen G 1983 Early morphologic and enzymatic changes in livers of rats treated with chenodeoxycholic and ursodeoxycholic acids. Hepatology 3: 201-208.
Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M 2001 Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27: 375-382. *
Shin DJ, Campos JA, Gil G, Osborne TF 2003 PGC-1alpha activates CYP7A1 and bile acid biosynthesis. J. Biol. Chem. 278: 50047-50052. *
Shoda J, Okada K, Inada Y, Kusama H, Utsunomiya H, Oda K, Yokoi T, Yoshizato K, Suzuki H 2007 Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol. Res. 37: 548-556. *
Shoda J, Tanaka N, Osuga T, Matsuura K, Miyazaki H 1990 Altered bile acid metabolism in liver disease: concurrent occurrence of C-1 and C-6 hydroxylated bile acid metabolites and their preferential excretion into urine. J. Lipid Res. 31: 249-259. *
Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ 2000 Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744. *
Sinal CJ, Yoon M, Gonzalez FJ 2001 Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids. J. Biol. Chem. 276: 47154-47162. *
Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R, Hum DW, Fruchart JC, Staels B 2004 The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 566: 173-177. *
Sirvent A, Verhoeven AJ, Jansen H, Kosykh V, Darteil RJ, Hum DW, Fruchart JC, Staels B 2004 Farnesoid X receptor represses hepatic lipase gene expression. J. Lipid Res. 45: 2110-2115. *
Sjovall J 2004 Fifty years with bile acids and steroids in health and disease. Lipids 39: 703-722.
Smit MJ, Temmerman AM, Wolters H, Kuipers F, Beynen AC, Vonk RJ 1991 Dietary fish oil-induced changes in intrahepatic cholesterol transport and bile acid synthesis in rats. J. Clin. Invest. 88: 943-951. *
Smit MJ, Verkade HJ, Havinga R, Vonk RJ, Scherphof GL, In 't Veld G, Kuipers F 1994 Dietary fish oil potentiates bile acid-induced cholesterol secretion into bile in rats. J. Lipid Res. 35: 301-310. *
Soccio RE, Breslow JL 2004 Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 24: 1150-1160. *
Sogawa K, Yamada T, Suzuki Y, Masaki T, Watanabe S, Uchida Y, Arima K, Nishioka M, Matsumoto K 1994 Elevation of ceruloplasmin activity involved in changes of hepatic metal concentration in primary biliary cirrhosis. Res. Commun. Chem. Pathol. Pharmacol. 84: 367-370.